Table 1. Outcomes in RTOG 0630 per CAN-NCIC-SR2 Trial Definitions.
| Year | Estimate, % (95% CI)a | Cumulative failures, No. | At risk, No. |
|---|---|---|---|
| Local recurrence | |||
| 0 | 100 (NA) | 0 | 73 |
| 1 | 95.6 (90.6-100) | 3 | 63 |
| 2 | 94.0 (88.2-99.7) | 4 | 57 |
| 3 | 92.2 (85.7-98.8) | 5 | 50 |
| 4 | 92.2 (85.7-98.8) | 5 | 45 |
| 5 | 92.2 (85.7-98.8) | 5 | 43 |
| Total | NA | 6 | NA |
| Regional/distant recurrence | |||
| 0 | 100 (NA) | 0 | 73 |
| 1 | 70.9 (60.5-81.4) | 21 | 50 |
| 2 | 65.3 (54.2-76.3) | 25 | 46 |
| 3 | 56.7 (45.2-68.2) | 31 | 39 |
| 4 | 56.7 (45.2-68.2) | 31 | 37 |
| 5 | 55.1 (43.6-66.7) | 32 | 36 |
| Total | NA | 32 | NA |
| Progression-free survival | |||
| 0 | 100 (NA) | 0 | 73 |
| 1 | 67.0 (56.2-77.8) | 24 | 48 |
| 2 | 61.5 (50.3-72.7) | 28 | 44 |
| 3 | 53.0 (41.5-64.5) | 34 | 37 |
| 4 | 51.5 (40.0-63.1) | 35 | 35 |
| 5 | 50.1 (38.5-61.6) | 36 | 34 |
| Total | NA | 39 | NA |
Abbreviations: CAN-NCIC-SR2, National Cancer Institute of Canada Sarcoma2; NA, not applicable; RTOG, Radiation Therapy Oncology Group.
a
Kaplan-Meier estimate of the percentage event-free.